Literature DB >> 22302059

The provisional ACR/EULAR definition of remission in RA: a comment on the patient global assessment criterion.

Marloes Vermeer1, Hillechiena H Kuper, Arie E van der Bijl, Henriëtte Baan, Marcel D Posthumus, Herman L M Brus, Piet L C M van Riel, Mart A F J van de Laar.   

Abstract

OBJECTIVES: The provisional ACR/European League Against Rheumatism (EULAR) definition of remission in RA requires a score of ≤1 on the patient global assessment (PGA, 0-10 scale). We explored the relation between the PGA criterion and the patient's clinical disease state in an observational dataset.
METHODS: Data of 512 newly diagnosed RA patients of the Dutch Rheumatoid Arthritis Monitoring (DREAM) remission induction cohort were analysed. Both 28-joint counts and more comprehensive joint counts (tender joint count-53, swollen joint count-44) were used.
RESULTS: ACR/EULAR remission was present in 20.1% of the patients when using 28-joint counts and in 17.4% of the patients when applying more comprehensive joint counts. In 108 patients, the PGA score was >1 despite fulfilment of the remaining criteria (TJC28, SJC28 and CRP in mg/dl ≤1). Residual disease activity was observed in 31.5% (34/108) and median (interquartile range) scores on PGA, pain and fatigue were 2.4 (1.8-4.0), 2.0 (1.1-3.0) and 2.7 (1.3-5.0), respectively. Applying more comprehensive joint counts showed comparable results. In 19.5% (100/512) of patients, disease activity was absent (TJC53 = 0, SJC44 = 0, and CRP ≤1). In 41% (n = 41) of these patients, the PGA score was >1. Receiver operating characteristic analysis showed moderate accuracy of the PGA to discriminate between fulfilment and no fulfilment of all remaining criteria.
CONCLUSION: Frequently, patients did not meet the PGA criterion despite a good clinical disease state. Apparently the PGA is not solely influenced by RA disease activity. In patients with marked divergence between the PGA and objective clinical measurements, caution should be taken when applying the provisional ACR/EULAR definition of remission.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22302059     DOI: 10.1093/rheumatology/ker425

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  15 in total

1.  Anti-allodynic action of the disease-modifying anti-rheumatic drug iguratimod in a rat model of neuropathic pain.

Authors:  K Morimoto; A Miura; Keiichi Tanaka
Journal:  Inflamm Res       Date:  2017-06-13       Impact factor: 4.575

2.  Phrasing of the patient global assessment in the rheumatoid arthritis ACR/EULAR remission criteria: an analysis of 967 patients from two databases of early and established rheumatoid arthritis patients.

Authors:  Laure Gossec; John Richard Kirwan; Maarten de Wit; Andra Balanescu; Cecile Gaujoux-Viala; Francis Guillemin; Anne-Christine Rat; Alain Saraux; Bruno Fautrel; Tore K Kvien; Maxime Dougados
Journal:  Clin Rheumatol       Date:  2018-02-21       Impact factor: 2.980

3.  Can rheumatoid arthritis ever cease to exist: a review of various therapeutic modalities to maintain drug-free remission?

Authors:  Di Liu; Na Yuan; Guimei Yu; Ge Song; Yan Chen
Journal:  Am J Transl Res       Date:  2017-08-15       Impact factor: 4.060

Review 4.  Rheumatoid arthritis in the elderly in the era of tight control.

Authors:  Martin Soubrier; Zuzana Tatar; Marion Couderc; Sylvain Mathieu; Jean-Jacques Dubost
Journal:  Drugs Aging       Date:  2013-11       Impact factor: 3.923

5.  Assessment of global disease activity in RA patients monitored in the METEOR database: the patient's versus the rheumatologist's opinion.

Authors:  Emilia Gvozdenović; Rosanne Koevoets; Ron Wolterbeek; Désirée van der Heijde; Tom W J Huizinga; Cornelia F Allaart; Robert B M Landewé
Journal:  Clin Rheumatol       Date:  2013-09-26       Impact factor: 2.980

6.  Further optimization of the reliability of the 28-joint disease activity score in patients with early rheumatoid arthritis.

Authors:  Liseth Siemons; Peter M ten Klooster; Harald E Vonkeman; Mart A F J van de Laar; Cees A W Glas
Journal:  PLoS One       Date:  2014-06-23       Impact factor: 3.240

Review 7.  Patient global assessment in measuring disease activity in rheumatoid arthritis: a review of the literature.

Authors:  Elena Nikiphorou; Helga Radner; Katerina Chatzidionysiou; Carole Desthieux; Codruta Zabalan; Yvonne van Eijk-Hustings; William G Dixon; Kimme L Hyrich; Johan Askling; Laure Gossec
Journal:  Arthritis Res Ther       Date:  2016-10-28       Impact factor: 5.156

8.  Limiting factors to Boolean remission differ between autoantibody-positive and -negative patients in early rheumatoid arthritis.

Authors:  Serena Bugatti; Ludovico De Stefano; Antonio Manzo; Garifallia Sakellariou; Blerina Xoxi; Carlomaurizio Montecucco
Journal:  Ther Adv Musculoskelet Dis       Date:  2021-05-22       Impact factor: 5.346

9.  Neuropathic-like pain features and cross-sectional associations in rheumatoid arthritis.

Authors:  Sanne M W Koop; Peter M ten Klooster; Harald E Vonkeman; Laura M M Steunebrink; Mart A F J van de Laar
Journal:  Arthritis Res Ther       Date:  2015-09-03       Impact factor: 5.156

10.  Comparison of remission criteria in a tumour necrosis factor inhibitor treated rheumatoid arthritis longitudinal cohort: patient global health is a confounder.

Authors:  Emese Balogh; Joao Madruga Dias; Carl Orr; Ronan Mullan; Len Harty; Oliver FitzGerald; Phil Gallagher; Miriam Molloy; Eileen O'Flynn; Alexia Kelly; Patricia Minnock; Madeline O'Neill; Louise Moore; Mairead Murray; Ursula Fearon; Douglas J Veale
Journal:  Arthritis Res Ther       Date:  2013-12-24       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.